Printer Friendly

OSTEOTECH PROMOTES ROGER STIKELEATHER TO EXECUTIVE VICE PRESIDENT MARKETING AND SALES

 SHREWSBURY, N.J., June 2 /PRNewswire/ -- Osteotech, Inc. (NASDAQ: OSTE) announced today that Roger C. Stikeleather has been appointed executive vice president of marketing and sales in recognition of the increased importance of direct marketing to Osteotech's strategic posture and current performance. Mr. Stikeleather joined Osteotech in 1988 and has served as senior vice president of marketing and sales. Prior to this, he directed the national sales and marketing organization for a division of Johnson and Johnson Products Inc.
 As previously reported, revenues in the first quarter of 1993 increased 63 percent to $4,740,000 from $2,914,000 in the first quarter of 1992. Excluding revenues from HC Implants, BV, acquired by the company in the second quarter of 1992, revenues increased approximately 37 percent. This growth in revenues has been achieved over the past year as a result of the company's strategic decision to develop and expand its direct marketing force, which currently includes 20 field representatives. This promotion reflects Mr. Stikeleather's role in this growth.
 Patrick A. McBrayer, president and chief executive officer of Osteotech, stated "This increased responsibility for Mr. Stikeleather is very important for the company. Our direct marketing and sales organization has achieved significant penetration in our target market of orthopaedic and neurosurgery. Consistent with our long-term strategic goals, we are preparing to conduct test marketing of products developed by others which will complement our current technology and call pattern and will help to further diversify our product mix. I believe this appointment, along with other further increased sales and marketing capability, will help maintain Osteotech's revenue growth."
 Osteotech, Inc., headquartered in Shrewsbury, is a leading processor of human bone and bone connective tissue for transplantation and an innovator in the development of biologic and biomaterial products for musculoskeletal surgery.
 -0- 6/2/93
 /CONTACT: Michael J. Jeffries of Osteotech, 908-542-2800/
 (OSTE)


CO: Osteotech, Inc. ST: New Jersey IN: MTC SU: PER

SH-PS -- NY019 -- 4345 06/02/93 09:36 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 2, 1993
Words:328
Previous Article:VIRAL TESTING SYSTEMS WILL FOCUS ON THE ONLY FDA APPROVED TEST THAT CAN BOTH SCREEN AND CONFIRM FOR HIV; DR. HERMANN MUCKE WILL HEAD R&D
Next Article:BROWNING-FERRIS DECLARES REGULAR QUARTERLY DIVIDEND
Topics:


Related Articles
OSTEOTECH APPOINTS DR. POSER AS R&D HEAD
OSTEOTECH ANNOUNCES MANAGEMENT CHANGES
KENNETH P. FALLON, III ELECTED TO OSTEOTECH BOARD OF DIRECTORS
Osteotech Announces Departure of Stikeleather.
Osteotech Announces Domestic Sales and Marketing Organization Changes.
Osteotech, Inc. Elects New Senior Vice President, Sales & Marketing.
Osteotech Appoints Mark H. Burroughs to Succeed Retiring CFO, Michael J. Jeffries.
Osteotech expanding its senior management team.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters